ELI LILLY & Co is 279.0x more valuable than CATALYST PHARMACEUTICALS, INC. by market capitalization ($1.070 T vs $3.84 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CPRX | LLY |
|---|---|---|
| Market cap | $3.84 B | $1.070 T |
| US-listed rank | #1606 | #10 |
| Revenue (latest FY) | $588.99M | $65.18B |
| Net income (latest FY) | $214.33M | $20.64B |
| Net margin | 36.4% | 31.7% |
| P/E (trailing FY) | 17.9 | 51.8 |
| SEC filings | 1,337 | 989 |
ELI LILLY & Co is 279.0x more valuable than CATALYST PHARMACEUTICALS, INC. by market capitalization ($1.070 T vs $3.84 B).
In their latest fiscal years, CATALYST PHARMACEUTICALS, INC. reported $588.99M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: CATALYST PHARMACEUTICALS, INC. and ELI LILLY & Co, or browse the full rankings.